With five observations Alembic Pharmaceuticals announced that United States Food and Drug Administration (USFDA)
has conducted an inspection at Alembic Pharmaceuticals New Injectable Facility
(F-3) located at Karkhadi from 29 January 2021 to 5 February 2021. This was a
scheduled inspection and at the end of the inspection, the USFDA issued a Form 483
with 5 observations.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.) Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keep